Patel H, Gupta V, Jain K, Yagnik P, Nair N, Reddy G
Indian J Orthop. 2025; 59(2):173-180.
PMID: 39886277
PMC: 11775356.
DOI: 10.1007/s43465-024-01327-9.
Levi S, Landau D, Davidovits M, Rootman M, Brener A, Gal S
Front Pediatr. 2024; 12:1487890.
PMID: 39687707
PMC: 11646759.
DOI: 10.3389/fped.2024.1487890.
Elwadhi A, Paharia K, Alam S, Sagar S, Kaur K
Indian J Pediatr. 2024; 92(2):215.
PMID: 39614035
DOI: 10.1007/s12098-024-05338-0.
Roy A, Chowdhury A, Ray A, Baidya A, Roychowdhury B, Sarkar D
Ann Pediatr Endocrinol Metab. 2024; 29(5):284-307.
PMID: 39506343
PMC: 11541088.
DOI: 10.6065/apem.2448044.022.
Stauffer A, Raimann A, Penzkofer S, Ganger R, Radler C, Mindler G
Front Endocrinol (Lausanne). 2024; 15:1422356.
PMID: 39371933
PMC: 11450710.
DOI: 10.3389/fendo.2024.1422356.
Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study.
Michigami T, Kang H, Namba N, Ito N, Kubota T, Shintani A
JBMR Plus. 2024; 8(8):ziae079.
PMID: 39015507
PMC: 11250265.
DOI: 10.1093/jbmrpl/ziae079.
Burosumab Efficacy and Safety in Patients with X-Linked Hypophosphatemia: Systematic Review and Meta-analysis of Real-World Data.
Kiafzezi D, Stamati A, Karagiannis T, Goulis D, Christoforidis A
Calcif Tissue Int. 2024; 115(3):229-241.
PMID: 39008126
DOI: 10.1007/s00223-024-01250-z.
Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review.
Dodamani M, Kumar S, Bhattacharjee S, Barnabas R, Kumar S, Lila A
Arch Endocrinol Metab. 2024; 68:e230242.
PMID: 38788147
PMC: 11156178.
DOI: 10.20945/2359-4292-2023-0242.
Diagnosis, treatment, and management of rickets: a position statement from the Bone and Mineral Metabolism Group of the Italian Society of Pediatric Endocrinology and Diabetology.
Baroncelli G, Comberiati P, Aversa T, Baronio F, Cassio A, Chiarito M
Front Endocrinol (Lausanne). 2024; 15:1383681.
PMID: 38706696
PMC: 11066174.
DOI: 10.3389/fendo.2024.1383681.
Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period.
Ward L, Hogler W, Glorieux F, Portale A, Whyte M, Munns C
JBMR Plus. 2024; 8(1):ziad001.
PMID: 38690124
PMC: 11059996.
DOI: 10.1093/jbmrpl/ziad001.
Rickets Types and Treatment with Vitamin D and Analogues.
Biasucci G, Donini V, Cannalire G
Nutrients. 2024; 16(3).
PMID: 38337700
PMC: 10857029.
DOI: 10.3390/nu16030416.
The use of burosumab to treat autosomal-recessive hypophosphatemic rickets type 2: rationale and a first clinical experience.
Parolin M, Partigiani N, Benetti E, Longo G, Vidal E
J Nephrol. 2024; 37(5):1371-1374.
PMID: 38308754
DOI: 10.1007/s40620-023-01884-6.
Switching to burosumab from conventional therapy in siblings with relatively well-controlled X-linked hypophosphatemia.
Senoo S, Fujimoto M, Yamaguchi Y, Osaki M, Hanaki K, Namba N
Clin Pediatr Endocrinol. 2024; 33(1):27-34.
PMID: 38299174
PMC: 10825651.
DOI: 10.1297/cpe.2023-0043.
FGF23-related hypophosphatemic rickets preceding the onset of systemic lupus erythematosus: A juvenile case.
Tabei Y, Ohtsu Y, Shimada M, Wada A, Hamajima E, Osawa Y
Clin Case Rep. 2024; 12(1):e8420.
PMID: 38223518
PMC: 10784849.
DOI: 10.1002/ccr3.8420.
Linear growth of children with X-linked hypophosphatemia treated with burosumab: a real-life observational study.
Levy-Shraga Y, Levi S, Regev R, Gal S, Brener A, Lebenthal Y
Eur J Pediatr. 2023; 182(11):5191-5202.
PMID: 37707589
DOI: 10.1007/s00431-023-05190-y.
Approach to Rickets: Is It Calciopenic or Phosphopenic?.
Abseyi S, Siklar Z
Turk Arch Pediatr. 2023; 58(5):458-466.
PMID: 37427438
PMC: 10543743.
DOI: 10.5152/TurkArchPediatr.2023.23050.
X-linked hypophosphatemic rickets: from diagnosis to management.
Park E, Kang H
Clin Exp Pediatr. 2023; 67(1):17-25.
PMID: 37321578
PMC: 10764665.
DOI: 10.3345/cep.2022.01459.
Asfotase alfa improved skeletal mineralization and fracture healing in a child with MCAHS.
Kang M, Wu M, Crane J
Bone. 2023; 172:116778.
PMID: 37088336
PMC: 10214309.
DOI: 10.1016/j.bone.2023.116778.
An overview of CYP27B1 enzyme mutation and management: A case report and review of the literature.
Zamanfar D, Ghazaiean M
Clin Case Rep. 2023; 11(3):e7007.
PMID: 36879673
PMC: 9984874.
DOI: 10.1002/ccr3.7007.
Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries.
Mughal M, Baroncelli G, de Lucas-Collantes C, Linglart A, Magnolato A, Raimann A
Front Endocrinol (Lausanne). 2023; 13:1034580.
PMID: 36798486
PMC: 9928183.
DOI: 10.3389/fendo.2022.1034580.